| Trial ID: | L0360 |
| Source ID: | NCT01566006
|
| Associated Drug: |
Mycophenolate Mofetil (Mmf) ,Phosphodiesterase 5 Inhibitors , Carnitine
|
| Title: |
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
|
| Acronym: |
Myridian
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathy|Chronic Kidney Disease
|
| Interventions: |
DRUG: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
|
| Outcome Measures: |
Primary: proteinuria, 16 time points over 1 year., before beginging of the treatment - baseline, after 1,2,3,4 weeks, after 1,2,3,4,5,6,7,8,9,10,11,12 months of the beginning of the treatment |
|
| Sponsor/Collaborators: |
Sponsor: The Nazareth Hospital, Israel | Collaborators: Western Galilee Hospital-Nahariya
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-04
|
| Completion Date: |
2013-08
|
| Results First Posted: |
|
| Last Update Posted: |
2012-03-29
|
| Locations: |
Nazareth hospital (EMMS), Nazareth, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT01566006
|
